60 F
New York
Friday, May 7, 2021

Here’s Why Urovant Sciences [NASDAQ: UROV] Is Trading Higher Today?

Must read

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Shares of Urovant Sciences Ltd. [NASDAQ: UROV] soared 93.24% during the trading session of Friday. The company has disclosed that it has signed a merger agreement with Sumitovant Biopharma.

Sumitovant Biopharma will acquire Urovant Sciences for approximately $584 million in total equity value in an all-cash merger. The shareholders of Urovant Sciences will receive $16.25 per share in cash.

The special committee of the Urovant Board of Directors has approved the offer of Sumitovant Biopharma. The committee has observed that this offer will create exceptional value for the shareholders of Urovant Sciences.

As per the agreement, a wholly-owned subsidiary of Sumitovant will combine with and into Urovant with Urovant to continue the merger as a wholly-owned subsidiary of Sumitovant. Additionally, the deal will be executed after the approval of a majority of minority shareholders.

Urovant Sciences Ltd. [NASDAQ: UROV] shares were trading up 93.24% as it gained +16.00 at the time of writing on Friday. Urovant Sciences Ltd. [UROV] share price went from a low point around $6.55 to briefly over $15.98 in the past 52 weeks, though shares have since pulled back to $16.00. UROV market cap has remained high, hitting $269.60 million at the time of writing.

Agreement between Urovant and Sumitovant is anticipated to be completed in the 2021 quarter one. The company is also planning to introduce vibegron. It has submitted that the New Drug Application for vibegron to FDA. Furthermore, Urovant is projecting to get the approval of the FDA by December 26, 2020.

More articles

Latest article

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...

R1 RCM [NASDAQ: RCM] Announces Acquisition of VisitPay

R1 RCM Inc. disclosed Tuesday that it has decided to purchase VisitPay. The firm has inked an agreement to buy VisitPay for nearly...

Binance Coin Makes History as its Market Cap Reach $100 Billion

The market capitalization of Binance set new records as the exchange token of Binance and the native asset of Binance Smart Chain (BSC) touched...

Precipio [NASDAQ: PRPO] Roll Out Rapid COVID-19 Antibody test on Amazon Platform

Shares of Precipio, Inc. skyrocketed 40.35% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments...

TechX Ink Deal to Buy Fiat-to-Crypto Merchant Services Gateway XPort Digital

TechX Technologies Inc disclosed Monday that it has bought fiat-to-crypto merchant services gateway XPort digital. The firm has bought a 100% stake in XPort...

Lockheed [NYSE: LMT] Present F-35 Best and Final Offer to Finnish Government

Lockheed Martin Corporation disclosed that it has presented F-35 best and final offer (BAFO) on April 29, 2021, to the Finnish government. It...

Clene [NASDAQ: CLNN] Gets Two Patent Notice of Allowances

Clene Inc. disclosed that Clene Nanomedicine, Inc. U.S. Patent and Trademark Office has provided Notices of Allowance for two significant patent applications. Clene...